title: Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
abstract: Despite a modern validated regimen of chemotherapy, advanced pancreatic adenocarcinoma remains the fourth most common cause of cancer-related death worldwide. The phosphoinositide 3-kinase pathway (PI3K)/Akt/mammalian target of rapamycin (mTOR) is a major signaling pathway that may be activated in advanced pancreatic cancer. To highlight the potential interest of this targetable pathway in selected advanced pancreatic cancer patients, we report herein a patient with an activated PI3K mutation who was treated in a phase I trial evaluating a treatment combination including an mTOR inhibitor.
authors: SITEP (Service des Innovations Therapeutiques Précoces), Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France.
authors: Anas
authors: A
authors: Gazzah
authors: Daniel Barrios
authors: DB
authors: Gonzales
authors: Antonin
authors: A
authors: Levy
authors: Rastislav
authors: R
authors: Bahleda
authors: Michel
authors: M
authors: Ducreux
authors: Ludovic
authors: L
authors: Lacroix
authors: Jean Charles
authors: JC
authors: Soria
keywords: PI3K; molecular profiling; pancreatic cancer; targeted therapy